These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
629 related articles for article (PubMed ID: 28525381)
21. C6 Cell Injection into the Optic Nerve of Long-Evans Rats: A Short-Term Model of Optic Pathway Gliomas. Singh D; Dromel PC; Perepelkina T; Baranov P; Young M Cell Transplant; 2020; 29():963689720964383. PubMed ID: 33356508 [TBL] [Abstract][Full Text] [Related]
22. Ultrastructural characterization of the optic pathway in a mouse model of neurofibromatosis-1 optic glioma. Kim KY; Ju WK; Hegedus B; Gutmann DH; Ellisman MH Neuroscience; 2010 Sep; 170(1):178-88. PubMed ID: 20600672 [TBL] [Abstract][Full Text] [Related]
23. The oligodendroglial lineage marker OLIG2 is universally expressed in diffuse gliomas. Ligon KL; Alberta JA; Kho AT; Weiss J; Kwaan MR; Nutt CL; Louis DN; Stiles CD; Rowitch DH J Neuropathol Exp Neurol; 2004 May; 63(5):499-509. PubMed ID: 15198128 [TBL] [Abstract][Full Text] [Related]
24. Mice with GFAP-targeted loss of neurofibromin demonstrate increased axonal MET expression with aging. Su W; Xing R; Guha A; Gutmann DH; Sherman LS Glia; 2007 May; 55(7):723-33. PubMed ID: 17348023 [TBL] [Abstract][Full Text] [Related]
25. Neurofibromatosis-1 regulates mTOR-mediated astrocyte growth and glioma formation in a TSC/Rheb-independent manner. Banerjee S; Crouse NR; Emnett RJ; Gianino SM; Gutmann DH Proc Natl Acad Sci U S A; 2011 Sep; 108(38):15996-6001. PubMed ID: 21896734 [TBL] [Abstract][Full Text] [Related]
26. Neurofibromatosis Type 1 and tumorigenesis: molecular mechanisms and therapeutic implications. Gottfried ON; Viskochil DH; Couldwell WT Neurosurg Focus; 2010 Jan; 28(1):E8. PubMed ID: 20043723 [TBL] [Abstract][Full Text] [Related]
27. Preclinical cancer therapy in a mouse model of neurofibromatosis-1 optic glioma. Hegedus B; Banerjee D; Yeh TH; Rothermich S; Perry A; Rubin JB; Garbow JR; Gutmann DH Cancer Res; 2008 Mar; 68(5):1520-8. PubMed ID: 18316617 [TBL] [Abstract][Full Text] [Related]
30. Olig1/2-Expressing Intermediate Lineage Progenitors Are Predisposed to PTEN/p53-Loss-Induced Gliomagenesis and Harbor Specific Therapeutic Vulnerabilities. Verma R; Chen X; Xin D; Luo Z; Ogurek S; Xin M; Rao R; Berry K; Lu QR Cancer Res; 2023 Mar; 83(6):890-905. PubMed ID: 36634201 [TBL] [Abstract][Full Text] [Related]
32. p53 and NF 1 loss plays distinct but complementary roles in glioma initiation and progression. Gonzalez PP; Kim J; Galvao RP; Cruickshanks N; Abounader R; Zong H Glia; 2018 May; 66(5):999-1015. PubMed ID: 29392777 [TBL] [Abstract][Full Text] [Related]
33. CXCL12 alone is insufficient for gliomagenesis in Nf1 mutant mice. Sun T; Gianino SM; Jackson E; Piwnica-Worms D; Gutmann DH; Rubin JB J Neuroimmunol; 2010 Jul; 224(1-2):108-13. PubMed ID: 20554030 [TBL] [Abstract][Full Text] [Related]
34. Isocitrate Dehydrogenase Mutations Are Associated with Different Expression and DNA Methylation Patterns of OLIG2 in Adult Gliomas. Mo H; Magaki S; Deisch JK; Raghavan R J Neuropathol Exp Neurol; 2022 Aug; 81(9):707-716. PubMed ID: 35856894 [TBL] [Abstract][Full Text] [Related]
35. Clinical, histological, and molecular features of gliomas in adults with neurofibromatosis type 1. Romo CG; Piotrowski AF; Campian JL; Diarte J; Rodriguez FJ; Bale TA; Dahiya S; Gutmann DH; Lucas CG; Prichett L; Mellinghoff I; Blakeley JO Neuro Oncol; 2023 Aug; 25(8):1474-1486. PubMed ID: 36840626 [TBL] [Abstract][Full Text] [Related]